A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
53actual
Sites
27
Countries
Australia, Canada, Denmark +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-01 | actual | When the study began enrolling |
| Primary completion | 2026-02-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-26 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- MTAP-null Non-Small-Cell Lung Cancer
- MTAP-null Solid Tumors
Interventions
- Drug: Anvumetostat — also filed as AMG 193
- Drug: IDE397
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)
measured Day 1 up to Day 21
Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
measured Day 1 up to approximately 2.5 years
Part 1: Number of Participants Experiencing Serious Adverse Events (SAEs)
measured Day 1 up to approximately 2.5 years
Part 2: Objective Response (OR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
measured Day 1 up to approximately 2.5 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed